Posible uso de la psilocibina en el tratamiento psiquiátrico, incluyendo las secuelas de COVID-19
DOI:
https://doi.org/10.33448/rsd-v10i11.19259Palabras clave:
Psilocibina; Psiquiatría; Depresión; Ansiedad; Cuidados paliativos; Alucinógenos.Resumen
Este artículo analiza la acción de la psilocibina en el organismo humano y su potencial terapéutico como tratamiento principal o coadyuvante de ciertos trastornos psiquiátricos, más concretamente de la depresión y la ansiedad, como los que se dan en pacientes que reciben cuidados paliativos y se enfrentan al proceso de finalización de la vida, pero también en pacientes en los que el tratamiento convencional no ha mostrado eficacia. Estudios recientes también indican la posibilidad de utilizar la psilocibina en el tratamiento de las secuelas psiquiátricas a largo plazo derivadas del COVID. La literatura disponible indica que la psilocibina favorece el aumento de la calidad de vida, los cambios en la percepción del self, la percepción de la integralidad con el entorno y las experiencias espirituales, lo que es especialmente importante en los grupos de pacientes mencionados. Además, presenta pocos o ningún efecto secundario. Este trabajo realiza una revisión para ratificar la hipótesis del uso terapéutico de la psilocibina en la depresión y la ansiedad en las poblaciones que más pueden beneficiarse de la terapia psicodélica.
Citas
Aversi-Ferreira et al. (2013). Confrontation between ethnopharmacology and scientific results of the herbal medicaments from Brazil to be applied in primary health care. Journal of Medicinal Plants Research, 7(14), 845-856.
Barnby, J. M. & Mehta, M. A. (2018). Psilocybin and mental health-don't lose control. Front. Psychiatry, 3. DOI: https://doi.org/10.3389/fpsyt.2018.00293.
Bershad, A. K. et al. (2019). Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers. Biological Psychiatry, 86(10), 792-800. DOI: https://doi.org/10.1016/j.biopsych.2019.05.019.
Bloch, S. et al. (2007). Psychological adjustment of men with prostate cancer: a review of the literature. Biopsychosoc Med, 1(2). DOI: https://doi.org/10.1186/1751-0759-1-2.
Bonn-Miller, M. O. et al. (2007). Associations between psychedelic use, abuse, and dependence and lifetime panic attack history in a representative sample. J Anxiety Disord, 21(5), 730-41. DOI: https://doi.org/10.1016/j.janxdis.2006.09.014.
Byock, I. (2018). Taking Psychedelics Seriously. Journal of Palliative medicine, 21(4). DOI: https://doi.org/10.1089/jpm.2017.0684.
Carhart-Harris, R. L., Bolstridge, M., Day & C. M. J. et al (2018). Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235, 399-408. DOI: https://doi.org/10.1007/s00213-017-4771-x.
Carhart-Harris, R. L., Roseman, L. & Bolstridge, M. et al (2017). Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep, 7, 13187. DOI: https://doi.org/10.1038/s41598-017-13282-7.
Carhart-Harris, R. L. et al (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry 7, 619-627. DOI: https://doi.org/10.1016/S2215-0366(16)30065-7.
Chang, V. et al (2007). Pain and palliative medicine. Journal of rehabilitation research and development, 44(2), 279-94. DOI: https://doi.org/10.1682/JRRD.2006.06.0067.
Chochinov, H. M. et al. (2009). The landscape of distress in the terminally ill. J Pain Symptom Manage, 38(5), 641-9. DOI: https://doi.org/10.1016/j.jpainsymman.2009.04.021.
Chochinov, H. M. et al. (2008). The patient dignity inventory: a novel way of measuring dignity-related distress in palliative care. J Pain Symptom Manage, 36(6), 559-71. DOI: https://doi.org/ 10.1016/j.jpainsymman.2007.12.018.
Costa et al (2018). The Confrontation between Ethnopharmacology and Pharmacological Tests of Medicinal Plants Associated with Mental and Neurological Disorders. Evidence-Based Complementary and Alternative Medicine. DOI: https://doi.org/10.1155/2018/7686913.
Cowen, P. (2016). Altered states: psilocybin for treatment-resistant depression. Lancet Psychiatry, 3(7), 592-3. DOI: https://doi.org/10.1016/S2215-0366(16)30087-6.
Dos Santos, R. G. et al (2016). Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Therapeutic Advances in Psychopharmacology, 6(3), 193-213. doi: https://doi.org/10.1177/2045125316638008.
Dos Santos, R. G. et al (2018). Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety and substance use disorders: a systematic review of systematic reviews. Expert Review of Clinical Pharmacology, 11(9), 889-902. DOI: https://doi.org/10.1080/17512433.2018.1511424.
Dos Santos, R. G. & Hallak, J. E. C. (2019). Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms. Neurosci Biobehav Rev, 108, 423-434. DOI: https://doi.org/10.1016/j.neubiorev.2019.12.001.
Erritzoe, D. et al. (2018). Effects of psilocybin therapy on personality structure. Acta Psychiatric Scand, 138(5), 368-378. DOI: https://doi.org/10.1111/acps.12904.
Erritzoe, D. et al. (2019). Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenges. Springer Nature – Neuropsychopharmacology, 45(5), 804-810. DOI: 10.1038/s41386-019-0567-5
Gandy, S. (2017). Dying to live: The power of transcendence in the treatment of existential anxiety. Journal of Interdisciplinary Consciousness Studies, 1(2), 25-36. Retrieved from http://www.tjics.org/index.php/TJICS/article/view/14.
Griffiths, R. R.; Richards, W. A. & Mccann, U. et al. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268-283. DOI: https://doi.org/10.1007/s00213-006-0457-5.
Griffiths, R. R. et al. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181-1197. DOI: https://doi.org/10.1177/0269881116675513.
Gripp, S. et. al. (2007). Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol, 25(22), 3313-3320. DOI: https://doi.org/10.1200/JCO.2006.10.5411.
Halberstadt, A. L. (2015). Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behavioural Brain Research, 277, 99-120. DOI: https://doi.org/10.1016/j.bbr.2014.07.016.
Hebert, R. et al (2009). Preparing Family Caregivers for Death and Bereavement. Insights from Caregivers of Terminally III Patients. Journal Of Pain And Symptom Management, 37, 3-12. DOI: https://doi.org/10.1016/j.jpainsymman.2007.12.010.
Kelly, J. R. et al (2020). Psychedelic science in post-COVID-19 psychiatry. Irish Journal Of Psychological Medicine, 1–6. DOI: https://doi.org/10.1017/ipm.2020.94.
Kolva, E. et al. (2011). Anxiety in terminally ill cancer patients. J Pain Symptom Manage, 42(5), 691-701. DOI: https://doi.org/10.1016/j.jpainsymman.2011.01.013.
Kraehenmann, R. et al. (2015). Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Biological Psychiatry, 78, 572-581. DOI: https://doi.org/10.1016/j.biopsych.2014.04.010.
Kraehenmann, R. et al. (2016). The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. NeuroImage: Clinical, 11, 53-60. DOI: https://doi.org/10.1016/j.nicl.2015.08.009.
Lim, C. H.; Kangas, B. & Bergman, J. (2018). The Utility of Psilocybin in Managing Anxiety and Depression in Cancer Patients. Journal of Young Investigators. DOI: https://doi.org/10.22186/jyi.35.2.45-49.
Ly, C. et al. (2018). Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep, 23, 3170-82. DOI: https://doi.org/10.1016/j.celrep.2018.05.022.
McCorvy, J. D; Olsen, R. H. J. & Roth, B. L. (2016). Psilocybin for depression and anxiety associated with life-threatening illnesses. Journal of Psychopharmacology, 30(12), 1209-1210. DOI: https://doi.org DOI: http://dx.doi.org/10.1177/0269881116675771.
Mithoefer, M. C.; Grob, C. S & Brewerton, T. D. (2016). Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. Lancet Psychiatry, 3(5):481-8. DOI: http://dx.doi.org/10.1016/ S2215-0366(15)00576-3.
Nutt, D. (2016). Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future. Journal of Psychopharmacology, 30(12), 1163-1164. DOI: https://doi.org/10.1177/0269881116675754.
Passie, T. et al. (2002). The pharmacology of psilocybin. Addiction Biology, 7(4), 357-364. DOI: https://doi.org/10.1080/1355621021000005937.
Phelps A.C. et al. (2009). Association between religious coping and use of intensive life-prolonging care near death in patients with advanced cancer. Jama, 301(11), 1140-7. DOI: doi: https://doi.org/10.1001/jama.2009.341.
Preller, K. H. et al. (2017). The fabric of meaning and subjective effects in LSD- induced states depend on serotonin 2A receptor activation. Curr Biol, 27, 451–7. DOI: https://doi.org/ 10.1016/j.cub.2016.12.030.
Preller, K. H. et al. (2020). Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity. Biological Psychiatry, 88(2), 197-207. DOI:https://doi.org/10.1016/j.biopsych.2019.12.027.
Roseman, L.; Nutt, D. J. & Carhart-harris, R. L. (2018). Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front. Pharmacol, 17. DOI: https://doi.org/10.3389/fphar.2017.00974.
Roseman et al. (2018). Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression. Neuropharmacology. 142, 263-269. DOI: https://doi.org/10.1016/j.neuropharm.2017.12.041.
Ross, S. (2018). Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. International Review of Psychiatry, 30(4), 317-330.DOI: https://doi.org/10.1080/09540261.2018.1482261.
Ross S, et al. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol, 30(12), 1165-1180. DOI: https://doi.org/10.1177/0269881116675512.
Rubinstein, E. et al. (2015). A call to action: the global response to dementia through policy innovation. Dementia. 37p. Retrieved from https://www.wish.org.qa/wp-content/uploads/2018/01/WISH_Dementia_Forum_Report_08.01.15_WEB.pdf.
Rucker, J. J. H.; Iliff, J. & Nutt; D. J. (2018). Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology, 142:200-218. DOI: https://doi.org/ 10.1016/j.neuropharm.2017.12.040.
Salih, L. H; Kaushik, A. (2013). Mini Review on psychedelic drugs: illumination on the hidden aspects of mind. American Journal Of Phytomedicine And Clinical Therapeutics. 1(5), 432-444. Retrieved from https://www.imedpub.com/articles/mini-review-on-psychedelic-drugsillumination-on-the-hidden-aspects-of-mind.pdf.
Schmid, Y; Liechti M. E. (2018). Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology. 235, 535-45. DOI: https://doi.org/10.1007/s00213-017-4733-3.
Singewald, N. et al. (2015). Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders. Pharmacology & Therapeutics, 149, 150-190. DOI: https://doi.org/10.1016/j.pharmthera.2014.12.004.
Sorger, B. et al. (2007). Decision-making capacity in elderly, terminally ill patients with cancer. Behavioral Sciences & The Law, 25, 393-404. DOI: https://doi.org/10.1002/bsl.764.
Tancer M. & Johanson C. E. (2003). Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend, 72(1), 33-44. DOI:http://doi.org/10.1016/s0376-8716(03)00172-8.
Tylš, F.; Páleníček, T. & Horáček, J. (2014). Psilocybin – Summary of knowledge and new perspectives. European Neuropsychopharmacology, 24, 342-356. DOI: https://doi.org/10.1016/j.euroneuro.2013.12.006.
Valentiner D. P., Mounts N. S. & Deacon B. J. (2004). Panic attacks, depression and anxiety symptoms, and substance use behaviors during late adolescence. J Anxiety Disord, 18(5), 573-85. Retrieved from http://bases.bireme.br/cgibin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&src=goo-gle&base=ADOLEC&lang=p&nextAction=lnk&exprSearch=15275940&indexSearch=ID.
Watts, R. et al. (2017). Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression. Journal of Humanistic Psychology, 57(5), 1-45. DOI: https://doi.org/10.1177/0022167817709585.
Young K. S. et al. (2017). Treatment for social anxiety disorder alters functional connectivity in emotion regulation neural circuitry. Psychiatry Res Neuroimaging, 30(261), 44-51. DOI: https://doi.org/10.1016/j.pscychresns.2017.01.005.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2021 Myla Chistie Araujo Custodio Bonifácio; Pietra Bruna Batrbosa Bento; Kaynara Trevisan; Renata Cristina Pereira; Micheli Patricia de Fátima Magri; Tales Alexandre Aversi-Ferreira
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Los autores que publican en esta revista concuerdan con los siguientes términos:
1) Los autores mantienen los derechos de autor y conceden a la revista el derecho de primera publicación, con el trabajo simultáneamente licenciado bajo la Licencia Creative Commons Attribution que permite el compartir el trabajo con reconocimiento de la autoría y publicación inicial en esta revista.
2) Los autores tienen autorización para asumir contratos adicionales por separado, para distribución no exclusiva de la versión del trabajo publicada en esta revista (por ejemplo, publicar en repositorio institucional o como capítulo de libro), con reconocimiento de autoría y publicación inicial en esta revista.
3) Los autores tienen permiso y son estimulados a publicar y distribuir su trabajo en línea (por ejemplo, en repositorios institucionales o en su página personal) a cualquier punto antes o durante el proceso editorial, ya que esto puede generar cambios productivos, así como aumentar el impacto y la cita del trabajo publicado.
